Haleon (HLN) Share Price, News & Analysis

Company Overview

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other. Within these categories, there are long standing-brands – such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, paradontax and Centrum, which are used and trusted by millions of consumers around the world. These brands are built on trusted science, innovation and deep human understanding.

Key Stats

• Today's Range: 386 to 405.10
• 50-Day Range: 357.60 to 415
• 52-Week Range: 319.84 to 417.70
• Volume: 23.38 million shs
• Average Volume: 26.85 million shs
• Market Capitalization: £35.96 billion
• P/E Ratio: 33.51
• Dividend Yield: 1.51%
• Price Target: GBX 457
• Consensus Rating: Buy

Haleon Stock Analysis - MarketRank™

Haleon scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Haleon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Haleon has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Haleon is 33.51, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.01.

Price to Earnings Ratio vs. Sector

The P/E ratio of Haleon is 33.51, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.81.

Price to Earnings Growth Ratio

Haleon has a PEG Ratio of 1.49. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Haleon has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HLN.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Haleon has a dividend yield of 0.02%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Haleon does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Haleon is 50.46%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for HLN.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.18

News Sentiment

Haleon has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Haleon this week, compared to 1 article on an average week.

MarketBeat Follows

3 people have added Haleon to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Haleon insiders have bought more of their company's stock than they have sold. Specifically, they have bought £61,850.24 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

10.74% of the stock of Haleon is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.88% of the stock of Haleon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HLN Stock Analysis - Frequently Asked Questions

How have HLN shares performed this year?

Haleon's stock was trading at GBX 377.40 at the beginning of 2025. Since then, HLN stock has increased by 5.6% and is now trading at GBX 398.40.
View the best growth stocks for 2025 here.

How were Haleon's earnings last quarter?

Haleon plc (LON:HLN) announced its earnings results on Friday, February, 28th. The company reported $15.80 earnings per share for the quarter. Haleon had a trailing twelve-month return on equity of 6.54% and a net margin of 9.66%.

How do I buy shares of Haleon?

Shares of HLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Haleon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Haleon investors own include GSK (GSK), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Meta Platforms (META) and Unilever (ULVR).

Company Calendar

• Last Earnings: 2/28/2025
• Record date for 6/5 Dividend: 4/24/2025
• Ex-Dividend for 6/5 Dividend: 4/24/2025
• Today: 5/04/2025
• Dividend Payable: 6/05/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Consumer Goods
• Current Symbol: LON:HLN
• CIK: N/A
• Web: www.haleon.com
• Phone: 44 1932 822000
• Fax: N/A
• Employees: 25,408
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 457
• High Stock Price Target: GBX 457
• Low Stock Price Target: GBX 457
• Potential Upside/Downside: +14.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX 11.89
• Trailing P/E Ratio: 33.51
• Forward P/E Ratio: 20.43
• P/E Growth: 1.49
• Net Income: £1.07 billion
• Net Margins: 9.66%
• Pretax Margin: N/A
• Return on Equity: 6.54%
• Return on Assets: 4.45%

Debt

• Debt-to-Equity Ratio: 53.36
• Current Ratio: 0.84
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: £11.07 billion
• Price / Sales: 3.25
• Cash Flow: GBX 18.15 per share
• Price / Cash Flow: 21.95
• Book Value: GBX 182.02 per share
• Price / Book: 2.19

Miscellaneous

• Outstanding Shares: 9,025,597,051
• Free Float: N/A
• Market Cap: £35.96 billion
• Optionable: Not Optionable
• Beta: 0.19